1. The inhibition of succinate oxidation in both heart and liver mitochondria by the cardiotoxic anticancer antibiotic adriamycin in vitro was reversed to a large extent by exogenous ubiquinone-45. Inhibition of the oxidation of NAD+-linked substrates in heart and liver mitochondria responded differently to ubiquinone, the inhibition being reversed only in liver organelles. 2. Administration of adriamycin inhibited oxidative phosphorylation in rat heart, kidney and liver mitochondria, the inhibition being highest in the heart organelles (about 50% for both NAD+-linked substrates and succinate). Exogenous addition of ubiquinone to mitochondria isolated from drug-treated animals did not reverse the inhibition. 3. Administration of ubiquinone along with adriamycin did not change effectively the pattern of drug-mediated decrease in oxidative activity of the organelles, particularly in the heart.
1. The inhibition of succinate oxidation in both heart and liver mitochondria by the cardiotoxic anticancer antibiotic adriamycin in vitro was reversed to a large extent by exogenous ubiquinone-45. Inhibition of the oxidation of NAD+-linked substrates in heart and liver mitochondria responded differently to ubiquinone, the inhibition being reversed only in liver organelles. 2. Administration of adriamycin inhibited oxidative phosphorylation in rat heart, kidney and liver mitochondria, the inhibition being highest in the heart organelles (about 50% for both NAD+-linked substrates and succinate). Exogenous addition of ubiquinone to mitochondria isolated from drug-treated animals did not reverse the inhibition. 3. Administration of ubiquinone along with adriamycin did not change effectively the pattern of drug-mediated decrease in oxidative activity of the organelles, particularly in the heart. Even though the anthracycline antibiotic adriamycin ranks among the most potent anticancer drugs known at present, its therapeutic use is severely restricted by its extreme toxicity, particularly to heart muscles. Severe cumulative dosedependent cardiomyopathy, leading to congestive heart failure, is the most pronounced toxic sideeffect. Drug-induced structural and functional damage to mitochondria is believed to be responsible for myocyte mortality . The relation between functional injury to mitochondria and cardiomyopathy was underscored by the observation that adriamycin inhibited mitochondrial oxidation (Gosalvez et al., 1974; Mailer & Petering, 1976; Ferrero et al., 1976; Goormaghtigh et al., 1982) . A biochemical explanation for the selective susceptibility of heart tissue to the toxic action of the drug was provided by our observation that succinate oxidation by phosphorylating heart-muscle mitochondria is rendered tremendously sensitive to inhibition by adriamycin by the enzyme hexokinase (Muhammed et al., 1982a,b) . Tumour cells are characterized by large increases in hexokinase activity, more than 70% of which is associated with the mitochondrial fraction (Burstamante & Pedersen, 1977; Burstamante et al., 1981) . We previously reported that in drugtreated animals one-quarter of the amount of drug present in tissues is associated with the mitochondrial fraction (Muhammed & Kurup, 1983 ).
The structural similarity of adriamycin to ubiquinone, and the important role the lipid quinone plays in mitochondrial function as an oxidation-reduction component of the respiratory chain, have prompted investigators to explore whether administration of ubiquinone would afford relief from cardiotoxicity. Folkers et al. (1977) reported that the inhibition of NADH oxidase and succinate oxidase activities of bovine heart mitochondria by anthracycline quinones could be reversed by ubiquinone analogues. Administration of adriamycin to rabbits has been shown to suppress the succinate: ubiquinone reductase activity of heart mitochondria (Bertazzoli et al., 1976) . The antibiotic was also shown to inhibit the synthesis of ubiquinone in vitro . These observations suggested that the antibiotic might act as an antagonist of ubiquinone.
It has been claimed by many research groups that ubiquinone could alleviate symptoms of cardiotoxicity produced by adriamycin. Thus Ghione & Bertazzoli (1977) reported that administration of the lipid quinone to rabbits chronically treated with the antibiotic corrected the abnormalities in electrocardiogram patterns, haematology and some aspects of blood chemistry. In perfused rabbit and rat hearts, exogenous supply of ubiquinone was reported to reverse rapidly the toxic effects of the antibiotic Ohhara et al., 1981) . In this context it may be Vol. 217 pertinent that the mitochondria of human and rodent neoplastic tissue have been reported to contain only half the amount of ubiquinone normally present in mitochondria (Kishi et al., 1977) . The animals were killed by cervical dislocation, and mitochondria from liver, heart and kidney were isolated as described by Muhammed et al. (1982b) . To minimize variations, an equal number of control and drug-treated animals were killed at about 09:00h.
Oxidative phosphorylation was determined both manometrically and polarographically, as described previously (Muhammed et al., 1982b) .
Protein was measured by the biuret method, deoxycholate being used for solubilization (Gornall et al., 1949) . All solutions were prepared in water, double-distilled in an all-quartz apparatus. Solutions were adjusted to pH 7.4 before use.
Results

Effect of ubiquinone in vitro
We have shown that, under phosphorylating conditions, substrate oxidation by heart, kidney and liver mitochondria is inhibited by adriamycin in vitro, the concentration for 50% inhibition being in the range 0.5-1 mM. However, in the presence of the enzyme hexokinase, succinate oxidation by heart mitochondria becomes highly sensitive to inhibition by the drug, 50% inhibition being given by 5 pM-adriamycin (Muhammed et al., 1982a,b) . The effect of addition of ubiquinone on the inhibitory activity of adriamycin was tested with concentrations of the antibiotic that gave about 50% inhibition of oxygen uptake. The results are summarized in Table 1 .
With both heart and liver mitochondria, the inhibition by adriamycin of oxygen uptake was reversed to a large extent (85%) by addition of ubiquinone when succinate was the substrate. These results are in agreement with the studies of Kishi et al. (1977) with bovine heart mitochondria and ubiquinone-50. Similar experiments on the oxidation of NAD+-linked substrates yielded opposite effects with the two mitochondrial preparations. With both liver and heart mitochondria, oxidation was drastically suppressed by the addition of exogenous ubiquinone (Table 1 ). However, with liver mitochondria, ubiquinone could reverse (by 85%) the inhibition by the antibiotic. In contrast, ubiquinone did not reverse the inhibition in heart mitochondria ( Table 1 ). The inhibition of NADH oxidation by exogenous ubiquinone in bovine heart mitochondria has been noted by Kishi et al. (1977) , who, however, obtained a 50% reversal of the inhibition by adriamycin. Effect of adriamycin in vivo Consistent with our observations that adriamycin was a potent inhibitor of mitochondrial oxidative phosphorylation (Muhammed et al., 1982a,b) and that mitochondria in heart, liver and kidney accumulated the drug (Muhammed & Kurup, 1983) , the organelles isolated from the organs of adriamycin-treated animals showed decreased oxidative phosphorylation (Table 2) .
In kidney mitochondria, NAD+-linked oxidation was suppressed by 37% and succinate oxidation by 27%. Liver mitochondria were less susceptible, the inhibition being only about 20%. The inhibition was highest in heart mitochondria, NAD+-linked oxidation being depressed by 51% and succinate oxidation by 47%. The mitochondrial samples from kidney, liver and heart contained 220, 144 and 132pmol of the drug/mg of protein respectively (Muhammed & Kurup, 1983) . The greater susceptibility of heart mitochondria to the inhibitory action of the drug and its metabolites is evident.
The results in Table 2 indicated that treatment with adriamycin did not affect the phosphorylation capacity of mitochondria; the P/O ratio did not show any change. However, in vitro the drug showed uncoupling properties (Muhammed et al., 1982b) . In the manometric method, the large excess of hexokinase present would tend to minimize the uncoupling action of the drug by making ATP limiting and thus unavailable for hydrolysis (Slater, 1966) . To eliminate this possibility, oxidative phosphorylation was measured Table 4 . g/.Ject of exogenous ubiquinone on-substrate oxidation by cardiac and hepatic mitochondria ofadriamycin-treated rats
The reaction system and method of assay were the same as described in the legend of Table 1, except that mitochondria isolated from heart and liver of rats which were given the drug (0.5 mg/rat per day, intraperitoneally) were also used as indicated. Oxygen-uptake values (ng-atoms of 0/min per mg of mitochondrial protein) are means + S.D. for four independent determinations (animals). Table 5 . Effect of administration of ubiquinone and adriamycin on oxidative activity of rat heart and liver mitochondria Animals were given adriamycin (0.5mg/rat per day) intraperitoneally and ubiquinone-45 (0.5mg/rat per day) orally in peanut oil for 8 days as indicated. Oxidation was measured by the manometric procedure. Values are means + S.D. for seven independent determinations for the heart, and means of two determinations for liver mitochondria. observed in the inhibitory studies in vitro reported by Muhammed et al. (1982b) . Ferrero et al. (1976) reported that mitochondria isolated from the hearts of rabbits intermittently treated with adriamycin showed a decrease in respiratory control largely due to a 30% increase in State-4 oxidation. We decided to see whether the decrease in oxidation in mitochondria isolated from drug-fed animals could be corrected by addition of ubiquinone in the reaction system. The results presented in Table 4 make it abundantly clear that ubiquinone does not reverse the inhibition in either heart or liver mitochondria.
Effect of ubiquinone in vivo
Ubiquinone administered along with adriamycin did not bring about any effective change in the drug-mediated decrease in the oxidative activity of heart mitochondria, irrespective of the type of substrate being oxidized ( (Table 5 ). However, as noted above (Table 2) , the inhibitory influence of adriamycin on the oxidation of NAD +-linked substrates by liver mitochondria is not pronounced.
Discussion
The results presented in this paper, which demonstrate substantial inhibition of the rate of substrate oxidation by mitochondria isolated from the organs of drug-treated animals, are consistent with and explicable on the basis of our previous work (Muhammed et al., 1982a,b; Muhammed & Kurup, 1983) . These findings, particularly the higher inhibition of oxidation shown by heart mitochondria despite the concentration of the drug in the organ being no more than in other organs such as the liver, lend support to the widely held notion that functional damage to mitochondria is a principal factor in the extreme cardiac toxicity of the drug.
The demonstration that the inhibitory action of added adriamycin on the oxidative activity of isolated mitochondria could be reversed to some extent by ubiquinone in vitro (Kishi et al., 1977) has kindled hopes of using the lipid quinone as an antidote for the toxicity of the antibiotic. The observation in many laboratories Ohhara et al., 1981) that some symptoms of cardiac toxicity were relieved by administration of ubiquinone added physiological relevance to the inferences made from the studies in vitro. Viewed in this light, experiments on the effects of ubiquinone administration on mitochondrial oxidative phosphorylation in drugtreated animals assume importance.
The results presented in this paper clearly show that, when administered together, ubiquinone does not reverse the deleterious effects of adriamycin on the oxidative function of cardiac mitochondria (Table 5) . Also, ubiquinone does not stimulate substrate oxidation when added to mitochondria isolated from adriamycin-fed animals. However, when added with adriamycin to normal mitochondria, the lipid quinone could reverse the inhibitory action of the drug on succinate oxidation, which is the most sensitive reaction (Table 1; Muhammed et al., 1982a,b) . This raises the question whether exogenously administered ubiquinone permeates the organ. According to Jayaraman et al. (1963) , ubiquinone administered by any route (oral, intracardial or intraperitoneal) does not penetrate the heart. More recently, Nakamura et al. (1980) have claimed that a small fraction (0.07%) of intravenously injected ubiquinone-50 enters rat heart, and about one-fifth of this is transferred to the mitochondrial inner membrane. Evidently the concentration of ubiquinone entering the organelles will be too meagre to be of any physiological significance.
Moreover, entry of the quinone into an organ or organelles may not be the decisive factor for physiological efficacy, because in the liver, which is known to accumulate a major portion of exogenously administered ubiquinone (Jayaraman et al., 1963) , reversal of inhibition is confined to NAD+-linked substrates (Table 5 ). It is possible that, to be physiologically functional, the quinone has to be associated with a specific binding protein (Yu & Yu, 1981) . It may also be pertinent that, in instances in which amelioration of clinical symptoms of adriamycin toxicity to the heart was shown, prolonged administration of ubiquinone before treatment with the drug was required ). It appears that the protective action of ubiquinone rests largely on its antioxidant properties (Yamanaka et al., 1980) , is not specific for adriamycin and related drugs, but is shown in conditions such as ischaemia (Katagiri et al., 1981) . The ability of the drug to interact with mitochondrial redox systems and to generate free radicals is well documented (Donehower et al., 1979; Davies et al., 1983; Gutierrez et al., 1983) . The possibility of ubiquinone interacting with the drug outside the mitochondrial membrane is also indicated by our results.
